Cumulative inactivated vaccine exposure and allergy development among children: a birth cohort from Japan

Environmental Health and Preventive Medicine

Japan Environment and Children’s Study (JECS) Group¹  Mayako Saito-Abe²  Limin Yang²  Miori Sato²  Yukihiro Ohya²  Kiwako Yamamoto-Hanada²  Kyongsun Pak³  Kazue Ishitsuka⁴  Kenji Matsumoto⁴  Hirohisa Saito⁴  Hidetoshi Mezawa⁴  Hatoko Sasaki⁴  Mizuho Konishi⁴  Minaho Nishizato⁴ 

[1] ;Allergy Center, National Center for Child Health and Development;Division of Biostatistics, Department of Data Management, Center for Clinical Research and Development, National Center for Child Health and Development;Medical Support Center for the Japan Environment and Children’s Study, National Research Institute for Child Health and Development;

关键词: Adjuvant;    Asthma;    Eczema;    Wheeze;    Inactivated vaccine;   

DOI  :  10.1186/s12199-020-00864-7

来源: DOAJ

【 摘 要 】

Abstract Background Adjuvants used in inactivated vaccines often upregulate type 2 immunity, which is dominant in allergic diseases. We hypothesised that cumulative adjuvant exposure in infancy may influence the development of allergies later in life by changing the balance of type 1/type 2 immunity. We examined the relationship between immunisation with different vaccine types and later allergic disease development. Methods We obtained information regarding vaccinations and allergic diseases through questionnaires that were used in The Japan Environment and Children’s Study (JECS), which is a nationwide, multicentre, prospective birth cohort study that included 103,099 pregnant women and their children. We examined potential associations between the initial vaccination before 6 months of age and symptoms related to allergies at 12 months of age. Results Our statistical analyses included 56,277 children. Physician-diagnosed asthma was associated with receiving three (aOR 1.395, 95% CI 1.028–1.893) or four to five different inactivated vaccines (aOR 1.544, 95% CI 1.149–2.075), compared with children who received only one inactivated vaccine. Similar results were found for two questionnaire-based symptoms, i.e. wheeze (aOR 1.238, 95% CI 1.094–1.401; three vaccines vs. a single vaccine) and eczema (aOR 1.144, 95% CI 1.007–1.299; four or five vaccines vs. a single vaccine). Conclusions Our results, which should be cautiously interpreted, suggest that the prevalence of asthma, wheeze and eczema among children at 12 months of age might be related to the amount of inactivated vaccine exposure before 6 months of age. Future work should assess if this association is due to cumulative adjuvant exposure. Despite this possible association, we strongly support the global vaccination strategy and recommend that immunisations continue. Trial registration UMIN000030786 .

【 授权许可】

Unknown